UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of **October 2017**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein are the following exhibits:

99.1 Press Release: Evogene Announces Revised and Expanded Market Focus and New Corporate Structure.

99.2 A Slide Presentation for Investors – October 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: October 30, 2017

By: /s/ Alex Taskar

Alex Taskar
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Press Release: Evogene Announces Revised and Expanded Market Focus and New Corporate Structure.
99.2	A Slide Presentation for Investors – October 2017.

Exhibit 99.1

Evogene Announces Revised and Expanded Market Focus and New Corporate Structure

Revised market focus involves leveraging its predictive biology platform to new areas in both agriculture and other fields, with emphasis on opportunities for further downstream product development and nearer term commercialization

Rehovot, Israel – October 30, 2017 Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform, announced today that it has revised and expanded its market areas of focus and established a new corporate structure consistent with these changes. The Company's revised focus includes both agriculture and other market areas, and will emphasize further downstream product development and shorter-term commercialization or other value enhancing opportunities.

Ofer Haviv, Evogene's President and CEO stated: "Evogene's unique discovery capabilities have been well demonstrated by platform based collaborations with world leading companies such as Bayer, BASF, DuPont-Pioneer, Monsanto, and Syngenta. These past and ongoing collaborations have resulted in the transfer to our partners of thousands of Evogene discoveries, largely in the form of genetic elements, small molecules and microbes, for potential product development under milestone and royalty bearing agreements.

Mr. Haviv continued, "Moving forward, the recent changes in market focus being announced today were selected following an extensive evaluation by the Company with the assistance of external consultants. The goal was to select from the many attractive product opportunities, both in agriculture and otherwise, that should result in enhanced shareholder value within the shortest possible time period. This activity selection was made possible due to our proven market-leading capabilities to integrate, interconnect and analyze massive amounts of biological data of different types from multiple sources – which we refer to as "Connecting the Dots" – being at the heart of all our product development efforts.

Mr. Haviv continued, "In order to move forward with maximum effectiveness we have put in place a new corporate structure, and I am very pleased by the rapid progress we are already seeing across all of our chosen focus activities."

Under the new structure, the enhancement, operation and maintenance of the company's computational predictive biology platform continues to be led by Mr. Yuval Ben-Galim, Evogene's EVP Technology & Operations (former COO). This platform, combining cutting-edge computational technologies, including artificial intelligence (AI), with deep biological understanding, continues to demonstrate - in an increasing number of major markets - the ability to identify key biological understandings and differentiators for the development of innovative products. The platform was developed at Evogene during the past decade by a multi-disciplinary team of scientists, computational and data scientists, with an investment of approximately $100 million and it continues to be enhanced and expanded. For more details please visit Evogene's website (www.evogene.com).

Evogene's discovery and product development programs in the field of agriculture, both pursuant to collaborations and self-funded activities, are now positioned in three operating divisions.

Ag-Biologicals - led by Mr. Ido Dor, EVP and GM Ag-Biologicals (former EVP & GM Crop Enhancement). The focus of this unit is the development of microbial based yield improvement and pest control products. In the scope of Ag-Biologicals, we have recently entered a collaboration with DuPont-Pioneer for the development of bio-stimulants in corn, and additionally have internal programs for bio-stimulants in wheat and bio-pesticides.

Ag-Chemicals - led by Mr. Eran Kosover, EVP & GM Ag-Chemicals (former EVP & GM Crop Protection), and is focused on the development of novel herbicides and insecticides, in addition to optimization of known active ingredients. In the scope of Ag-Chemicals we have ongoing collaborations with BASF and ICL, as well as a robust internal novel herbicide pipeline.

Ag-Seeds - led by Dr. Arnon Heyman, VP & GM Ag-Seeds (former director of project management). The main focus of the Ag-Seeds unit is improved seed traits, for yield increase, drought tolerance, insect control and disease resistance, through the use of genome editing and gene transformation. In the scope of Ag-Seeds we have a long-term collaboration with Monsanto as well as with other market leading companies in addition to an internal pipeline.

In the Ag-Seeds market segment, Evogene's primary activities, with respect to past discoveries, consist of supporting gene advancement in its partners' development pipelines and less focused on the discovery of new genes. The discovery of new genes and their validation in model plants was a very substantial activity for Evogene in the past, particularly pursuant to our collaboration with Monsanto, and resulted in thousands of discoveries transferred to our partners under collaboration agreements. Furthermore, Evogene's focus today is on the substantial proprietary knowledge obtained by its long-term efforts in this field, which is now a major component of the Ag-Seed unit's efforts in applying the newer genome editing technology. Genome editing is expected to be more regulatory friendly than gene transformation and potentially with a shorter time to market.

Beyond these three broad market areas in agriculture, it is the intent of Evogene to identify and pursue, generally through subsidiaries, other attractive opportunities meeting our revised market focus guidelines and where "Connecting the Dots" appears to be the key solution to innovative product development. In these situations, Evogene's predictive biology platform should provide the company with an important competitive advantage. At present, Evogene has two such subsidiaries.

Biomica is a recently established subsidiary whose mission is to discover and develop human microbiome-based therapeutics. Biomica represents Evogene's first effort to apply its predictive discovery capabilities in the field of human health. The subsidiary was co-founded, and is being led scientifically, by Yehdua Ringel, MD, professor of medicine, former associate director of the Center for Functional Gastrointestinal and Motility Disorders at the University of North Carolina at Chapel Hill and the former Chief of Gastroenterology at Beilinson Hospital, Rabin Medical Center in Israel.

The Company's second subsidiary, Evofuel, is focused on the development and commercialization of castor seeds, and will continue to be led by Mr. Assaf Dotan. Evofuel is now evaluating various commercial pathways for its first generation of improved castor seeds.

The updated corporate structure, while supporting Evogene's expanding areas of focus, will allow more efficient use of resources, resulting in an expected decrease in net cash usage in 2018 of 14M-16M USD (not including other potential revenue streams), from an expected net cash usage of 16M-18M USD in 2017.

Ofer Haviv, Evogene's President and CEO concluded: "During the past few years, Evogene has been evolving from a plant genomics company to a company addressing a wide variety of biological challenges with its unique, broadly applicable discovery and product optimization platform. We believe that our revised market focus and organizational structure will drive the company's growth and increase value for our shareholders. We look forward to reporting our continuing progress and achievements."

For more details please view company presentation, uploaded with this press release, at: http://www.evogene.com/investor-relations/presentations-and-webcasts/

About Evogene Ltd.:
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform. The Company has developed a proprietary innovative technology platform, leveraging scientific understanding & computational technologies to harness Ag 'Big Data' for developing improved seed traits (via: GM and non-GM approaches), as well as innovative ag-chemical and novel ag-biological products. Evogene has strategic collaborations with world-leading agricultural companies such as: BASF, Bayer, DuPont, Monsanto and Syngenta, focusing on innovative crop enhancement and crop protection solutions. For more information, please visit www.evogene.com.

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Contact:
Nir Zalik
IR/PR manager
E: IR@evogene.com
T: (+972)-8-931-1963

Exhibit 99.2

evogene
Plant Innovation

Company Presentation

October, 2017

Ofer Haviv, President & CEO

Safe Harbor Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

What We Do

We develop novel products for life-science markets...	...through the use of a unique computational predictive biology platform
	

About Us

- Evogene is a leading company for the development of novel products for life science markets through the use of a unique computational predictive biology (CPB) platform
- Today, focused on developing products in three fields in the Ag world: Seeds, Ag- Biologicals and Ag-Chemicals
- Two subsidiaries: Evofuel (100%) - Castor Seeds and Biomica (90%) - Human Microbiome
- Strategic collaborations over the years with world-leading companies such as BASF, Bayer, DuPont-Pioneer, Monsanto, Syngenta and ICL
- Revenue stream: (i) R&D payments, (ii) milestone payments (iii) royalties from product sales
- **An updated strategy was defined - consists of shorter time to market and more downstream activities**

Additional Facts:

- Located in Rehovot, Israel and St. Louis, Missouri, US
- ~160 employees, ~ 50 PhDs
- Traded on NASDAQ and TASE, covered by Credit Suisse and Piper Jaffray
- Cash position: ~80 million USD as of June 30th , 2017; no debt

Evogene – An Evolving Story

IPO TASE - IPO NYSE

2007 - 2013

Evofuel

Castor Seeds

Seed Traits

Yield & ABST

Plant Disease

Evogene – An Evolving Story



Evogene – An Evolving Story



Corporate Structure



Corporate Structure



Evogene's Unique Product Development Approach

Numerous criteria nowadays have made traditional linear methodology inefficient



Evogene takes product criteria into account at **Stage Zero**
focusing only on optimal product candidates



- Increasing probability of success
- Reducing time to market
- Reducing budget

‘Connecting the Dots’

Evogene has created an integrated technological predictive platform that combines **deep biological understanding** with **cutting-edge computational** technology

‘Connecting the Dots’

Evogene has created an integrated technological predictive platform that combines **deep biological understanding** with **cutting-edge computational** technology



The platform includes **intelligent** algorithms that **integrate and analyze** vast data within the eco-systems, **predicting cross dimensional interactions** within a **multi-dimensional space** this is what we refer to as - ***‘Connecting the Dots’***

Example of 'Connecting the Dots' for Novel Herbicides



Computational Predictive Biology (CPB) Platform



Validation and Development System










Partnerships Through the Years

Corporate Structure



Product Selection Considerations

- Large market opportunity and clear need for innovation
- The major industry roadblock to developing innovative products is the need to ***'Connect the Dots'***
- There is a clear path and reasonable time to commercialization and /or well-recognized value enhancing milestones during development period
- Leveraging on existing assets accumulated over the years to be able to form collaborations at an advanced stage of product development and at better financial terms
- Continuing work with partners on existing product programs, advancing discoveries in partners' pipelines to re-focus initial discovery outputs to more downstream potential product offerings
- Effective new products will contribute to human well-being

Corporate Structure



Ag Seeds – Market, Need & 'Connecting the Dots'

Ag Seeds
Biotechnology Seeds & Genomic Edited Seeds

Ag-Seeds - $37B[1] (2015)

- **Yield and environmental stress** - potential to increase yield and plant adaptability to environmental stress
- **Disease resistance** – limited seed trait solutions
- **Insect control -** overcome insect resistance to available commercial solutions

'Connecting the Dots'

1 Source: Phillips McDougall

Collaboration Example - Monsanto

- **Collaboration period -** 10 years
- **Objective -** improved seeds via biotechnology
  - **Crops -** corn, soybean, cotton, canola
  - **Traits -**
    - Yield, drought tolerance, fertilizer utilization
    - Disease resistance – Fusarium resistance in corn
- **Key terms -**
  - R&D and up-front payments - total ~$68M
  - Milestone payments + royalties from sales
  - $30M equity investment (including $12M in IPO)

evogene Plant Innovation

MONSANTO

Gene discovery and trait optimization	Development and commercialization

CPB | Model plant validation | Target plant validation and development | ***Improved seeds***

Genome Editing – New Promising Technology

- Novel method for improving seed traits
- Resulting products may be considered Non-GMO with shorter time to market
- Major opportunity for all crops and locations

Evogene's unique advantage – 'What to edit'
Technological capabilities, knowledge and proprietary plant genomics big data, allow the identification of required edit-targets for crop improvement



Genome Editing – Product Development Impact

Conventional GM route*:

8-16 years

New Genome Editing non GM route**:

5-8 years

Non GMO approval could be given at this stage

* Further details can be found in Evogene's 20-F filing, pg. 36
** According to industry estimates

Corporate Structure



Ag-Biologicals – Market, Need &'Connecting the Dots'

Ag Biologicals
Bio-stimulants & Bio-Pesticides

Ag-Biologicals - $3B[1] (2014)

- Expected to reach $9B in 2020
- Short time to market – according to industry estimates may take only 5 years from initial work to market, depending on regulation.
- Reduced development costs
- Need for novel solutions with stable performance
- Microbiome a promising source for innovation, now accessible via maturing technologies
- Industry leaders getting in on the action

'Connecting the Dots'



1 Source: Phillips McDougall

Collaboration Example - DuPont-Pioneer

- Initiated in 2017
- Objective - Develop and commercialize microbiome based bio-stimulant products that improve corn yield
- Current stage - Early development
- Activities -
  - Evogene and DuPont-Pioneer to further develop candidate products in target regions in the US
  - DuPont-Pioneer to commercialize products through its world-leading seed treatment business



Internal Program Example

Positive results in corn & wheat field bio-stimulants programs

Improved ear size and weight at harvest resulted with 17% increase of yield per plant

($p < 0.05$)

Improved vigor and biomass resulted with >15% increase in spikelet weight and yield per plant



EVM6810005 Non-inoculated

($p < 0.1$)

Upcoming milestone: conclusion of 2017 results and nomination of microbial teams for 2018 trials in US

Corporate Structure



Ag-Chemicals – Market, Need & 'Connecting the Dots'

Ag Chemicals
Herbicides & Insecticides

Ag-Chemicals - $50B[1] (2015)

- Crop protection Ag-chemicals responsible for ~50% of key crops yield
- Increasing pest resistance to existing products creates a strong need for novel Ag-chemicals

'Connecting the Dots'



1 Source: Phillips McDougall

Collaboration Example - BASF

- Initiated in 2015, collaboration period - 3 years
- Objective - Herbicides with new MOA
- Discovery stage
- Activities:
  - Evogene to identify novel targets and target-linked chemical candidates
  - BASF to screen & validate the chemical candidates and further develop successful candidates towards commercial products



Ag-Chemicals Internal Pipeline

evogene

2-3 years | 3-4 years | 3-4 years

Discovery → Pre-development → Development & registration

Target	Target identification	Computational Screen	Hit Validation	Hit-to-Lead	Lead optimization
Herbicides					
Targets I-VII	>10 Hits computationally linked to new targets				
Target VIII	AI optimization				
New targets	5 targets				
Insecticides					
Target I	AI optimization				
Targets II-IV	New SoAs				

Upcoming milestone – Initial Leads

efficacy improvement through optimization and target biological proof



Corporate Structure



Providing farmers with the most advanced castor seeds & ag-service solutions

The global castor oil and derivatives market is expected to reach USD 2.30 billion by 2024**

U.S. castor oil and derivatives market volume by product, 2014 - 2024 (KiloTons)



Source:
Grand View Research, August 2016, http://www.grandviewresearch.com/industry-analysis/castor-oil-derivatives-industry
**http://www.grandviewresearch.com/press-release/global-castor-oil-derivatives-industry

- Genomics & Technology- advanced breeding and varieties
- Seed production- Castor bean fields for the production of seeds
- Agro-technical support- Market specific crop protocols
- Mechanical harvesting solution support

Evofuel Global Footprints



Corporate Structure



Biomica

Discovery and development of human microbiome based therapeutics utilizing computational predictive biology (CPB) platform



Sources:
BCC Research (2017) – Human Microbiome-based Drugs and Diagnostics Market
SVB – Emerging Healthcare: Microbiome Investment Trends Aug 2017)

- ~$ 10Bn market opportunity by 2024
- $840M invested in microbiome space since 2010
- Big pharma and VCs deeply engaged

- Strong scientific correlation between human microbiome and a wide range of diseases
- Microbiome-based therapeutics may complement existing therapies in treating known diseases

Biomica – 'Connecting the Dots'

Multi-layer analysis in support of discovery of efficacious therapeutic candidates and disease biomarkers



Evogene's computational platform enables multi-layer analysis to support the discovery of highly efficacious therapeutic candidates and relevant microbiome-based biomarkers

Corporate Structure



Evogene Highlights

1	Unique technology platform (CPB), combining expertise in life science and cutting-edge computational technology – '*Connecting the Dots*'
2	Engine for next generation product for life science - targeting multi-billion dollar markets
3	Innovation partner-of-choice for industry leaders
4	Diversified product portfolio with clear paths to milestone payments and royalties
5	Strong balance sheet

evogene
Plant Innovation

Thank You

Contact:
investors@evogene.com
T: +972 8 931 1934

Appendix - Financials

Key Financials – Balance Sheet

Thousand US $	30.6.2017	31.12.2016
Current Assets	81,821	89,490
Long-Term Assets	5,625	6,496
Total Assets	**87,446**	**95,986**
Current Liabilities	4,633	5,225
Long-Term Liabilities	3,478	3,472
Shareholders Equity	79,335	87,289
Total Liabilities	**87,446**	**95,986**

Key Points:

- Cash position: 80 million USD as of 30.6.2017
- No debt
- Estimated net cash usage for 2017: $16-$18 million

Key Financials – P&L

Thousand US $	H1 2017	H1 2016	2016
Revenues	1,899	3,824	6,540
Gross Profit	234	734	901
Operating Loss	(10,426)	(9,765)	(21,089)
Net Loss	(9,590)	(7,835)	(19,592)

Key Points:

- Revenues consist primarily of R&D revenues, reflecting cost reimbursement under our collaboration agreements
- Advancement of our collaboration agreement with Monsanto reducing R&D revenues